<img height="1" width="1" src="https://www.facebook.com/tr?id=200201724533423&amp;ev=PageView &amp;noscript=1">
Contact Us

    GENOMIND PRESS ROOM

    January 13, 2021

    How pharmacogenetic (PGx) testing is revolutionizing mental health treatment

    If you or a family member have sought care from a mental health professional, or are considering seeking help for depression, anxiety, ADHD or other conditions, you want the best treatment available. Multiple treatment options now exist for many of these conditions, ranging from medications and psychotherapy to alternative treatments. It can be confusing to sort through your choices and determine what approach will give you or your loved one the ideal outcome.

    Continue Reading...
    December 18, 2020

    Are you susceptible to pandemic-related anxiety?

    Since the pandemic began, many have felt the effects on their mental health. The CDC reported in June that over 40% of Americans suffered an adverse mental or behavioral health condition, with anxiety and depressive disorders topping the list. By mid-July, 53% of U.S. adults said their mental health was negatively impacted by stress and worry due to the pandemic, according to a Kaiser Family Foundation poll. As the pandemic continues, these stressors are likely to impact more people every day.

    Continue Reading...
    November 11, 2020

    Genomind and Stop Soldier Suicide Partner in Mission to Reduce Soldier and Veteran Suicides

    Continue Reading...
    September 10, 2020

    Genomind Announces Major Industry-Leading HLA-A Test Innovation on its Comprehensive Mental Health Pharmacogenetics (PGx) Test, Increasing Utility for Tens of Thousands of Clinicians and Patients

    Summary:

    New patent-pending, real-time polymerase chain reaction (PCR) technique can accurately detect the human leukocyte antigen HLA-A*31:01 genetic variant, reducing the 40% false positive rate associated with the industry testing approach. Genomind’s® Professional PGx Express™ is now the only mental health pharmacogenetics (PGx) test using this capability in the market. Given the recent positive coverage decisions by major health insurers, Genomind will be leading national education efforts to make this innovation widely available to clinicians and patients

    Continue Reading...
    June 24, 2020

    Genomind Releases Mental Health Map Consumer DNA Test

    A breakthrough in the translation of genetic mechanisms and traits that can influence a person’s behavioral predispositions, Genomind Mental Health Map provides the starting point to empower consumers to take action towards better mental health and wellness
    Continue Reading...
    April 23, 2020

    Genomind Coordinates With Multiple Health Plans to Expand Access to Its Pharmacogenetics Tools and Help Reduce Mental Health-Related ER and Hospital Visits During the COVID-19 Crisis

    Demand for mental health tools and services skyrockets; SAMSHA crisis hotline reported 9 times the number of requests for mental health crisis support in March

    Continue Reading...

    SEARCH NEWS